Soon to Be Phase 1: ADI‑212 Off The Shelf CAR T Therapy for mCRPC

FDA has cleared the way for an early clinical trial of a new, off‑the‑shelf cell therapy designed to tackle metastatic castration‑resistant prostate cancer, a late and difficult stage of the disease. The investigational product, referred to in regulatory filings as ADI‑212, is a gene‑edited, “armored” gamma delta CAR T cell therapy that targets prostate‑specific membrane antigen (PSMA) and combines several engineering strategies intended to improve both potency and tolerability in solid tumors.

PSMA is a transmembrane protein that is overexpressed in more than 80% of prostate cancers and tends to be even more abundant in advanced disease, making it an attractive target for both imaging and therapy. Unlike many earlier PSMA‑directed CAR T approaches that used conventional alpha‑beta T cells, this program is built on gamma delta T cells, specifically the Vδ1 subset that naturally resides in tissues and can infiltrate tumor‑associated environments. In preclinical models, anti‑PSMA Vδ1 CAR T cells have shown strong cytotoxic activity against prostate cancer cell lines, robust proliferation, production of pro‑inflammatory cytokines, and meaningful tumor growth inhibition in xenograft and organoid systems.

The therapy does more than just add a PSMA‑targeting receptor. It uses a new CAR binder that locks onto a specific 3D shape on PSMA located on the outer part of the protein, a shape that only appears when two PSMA molecules pair up. This should make the cells better at recognizing prostate cancer and less likely to attack other tissues that have similar proteins, a key safety concern with earlier PSMA‑targeted therapies. The treatment is also “off‑the‑shelf”: it is made from healthy donor cells instead of each patient’s own cells, so it can be produced in advance and given more quickly and consistently than personalized CAR T products.

To help the cells work better inside solid tumors, they are engineered to carry interleukin‑12 (IL‑12) attached to their surface. IL‑12 is a strong immune signal that can boost killer T cells, natural killer cells, and other immune players, but giving it throughout the body has often caused serious side effects. By keeping IL‑12 fixed to the cell membrane, the therapy tries to concentrate this boost right where the CAR T cells meet the tumor, increasing local attack power while reducing exposure to the rest of the body.

A second engineering step uses CRISPR to switch off a gene called MED12 inside the CAR T cells. This “MED12 knockout” is part of an armoring strategy meant to make the cells more potent in solid tumors and able to use several anti‑tumor mechanisms at once inside the tumor microenvironment. Combined with the new PSMA binder and the membrane‑tethered IL‑12, this change is designed to overcome some of the main problems that have limited earlier CAR T therapies in solid tumors, such as short survival of the cells, strong immunosuppressive signals from the tumor, and poor infiltration into the tumor mass.

The regulatory clearance allows the first‑in‑human Phase 1 trial to proceed in patients with metastatic castration‑resistant prostate cancer, with enrollment expected to begin in the fourth quarter of 2026.

Source.